Literature DB >> 26614376

Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

Dik J Kwekkeboom1, Eric P Krenning2.   

Abstract

Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid; Neuroendocrine tumor; PRRT; Radionuclide therapy; Treatment

Mesh：

Substances：

Year:  2016        PMID： 26614376     DOI： 10.1016/j.hoc.2015.09.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  45 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

2.  Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Authors:  Jingjing Zhang; Hao Wang; Orit Jacobson; Yuejuan Cheng; Gang Niu; Fang Li; Chunmei Bai; Zhaohui Zhu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

3.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

Authors:  Mengshi Li; Xiuli Zhang; Thomas P Quinn; Dongyoul Lee; Dijie Liu; Falk Kunkel; Brian E Zimmerman; Daniel McAlister; Keith Olewein; Yusuf Menda; Saed Mirzadeh; Roy Copping; Frances L Johnson; Michael K Schultz
Journal:  Appl Radiat Isot       Date:  2017-05-10       Impact factor: 1.513

Review 4.  Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2017-03

5.  Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Chiara Liverani; Alberto Bongiovanni; Laura Mercatali; Federica Pieri; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Flavia Foca; Sara Ravaioli; Alessandro De Vita; Claudia Cocchi; Giulio Rossi; Federica Recine; Toni Ibrahim
Journal:  Endocr Pathol       Date:  2021-01-06       Impact factor: 3.943

Review 6.  Update in the Therapy of Advanced Neuroendocrine Tumors.

Authors:  Inbal Uri; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 7.  The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.

Authors:  Lisa Bodei; Jarosław B Ćwikla; Mark Kidd; Irvin M Modlin
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 8.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

9.  Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jacob A Martin; Richard R P Warner; Anne Aronson; Juan P Wisnivesky; Michelle Kang Kim
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 10.  Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.